Department of Hospital Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Urology Section, Minneapolis VA Health Care System, Minneapolis, MN, USA.
BJU Int. 2024 Feb;133(2):132-140. doi: 10.1111/bju.16220. Epub 2023 Nov 29.
OBJECTIVES: To assess the effects of percutaneous nephrolithotomy (PCNL) vs retrograde intrarenal surgery (RIRS) for the treatment of renal stones in adults. METHODS: We performed a comprehensive search of the Cochrane Library, MEDLINE, Embase, three other databases, trials registries, other sources of the grey literature, and conference proceedings up to 23 March 2023. We applied no restrictions on publication language or status. Screening, data extraction, risk-of-bias assessment, and certainty of evidence (CoE) rating using the Grading of Recommendations Assessment, Development and Evaluations (GRADE) approach were done in duplicate by two independent reviewers. This co-publication focuses on the primary outcomes of this review only. RESULTS: We included 42 trials that met the inclusion criteria. Stone-free rate (SFR): PCNL may improve SFRs (risk ratio [RR] 1.13, 95% confidence interval [CI] 1.08-1.18; I = 71%; 39 studies, 4088 participants; low CoE). Major complications: PCNL probably has little to no effect on major complications (RR 0.86, 95% CI 0.59-1.25; I = 15%; 34 studies, 3649; participants; moderate CoE) compared to RIRS. Need for secondary interventions: PCNL may reduce the need for secondary interventions (RR 0.31, 95% CI 0.17-0.55; I = 61%; 21 studies, 2005 participants; low CoE) compared to RIRS. CONCLUSION: Despite shortcomings in most studies that lowered our certainty in the estimates of effect to mostly very low or low, we found that PCNL may improve SFRs and reduce the need for secondary interventions while not impacting major complications. Ureteric stricture rates may be similar compared to RIRS. We expect the findings of this review to be helpful for shared decision-making about management choices for individuals with renal stones.
目的:评估经皮肾镜碎石术(PCNL)与逆行性肾内手术(RIRS)治疗成人肾结石的效果。
方法:我们全面检索了 Cochrane 图书馆、MEDLINE、Embase、另外三个数据库、试验注册处、灰色文献的其他来源和会议记录,检索截至 2023 年 3 月 23 日。我们对发表语言或状态没有任何限制。两名独立评审员重复进行筛选、数据提取、偏倚风险评估和使用 Grading of Recommendations Assessment, Development and Evaluations(GRADE)方法进行证据确定性(CoE)评级。本合作出版物仅重点关注本综述的主要结局。
结果:我们纳入了符合纳入标准的 42 项试验。结石清除率(SFR):PCNL 可能提高 SFR(风险比 [RR] 1.13,95%置信区间 [CI] 1.08-1.18;I = 71%;39 项研究,4088 名参与者;低 CoE)。主要并发症:与 RIRS 相比,PCNL 对主要并发症可能影响较小或无影响(RR 0.86,95%CI 0.59-1.25;I = 15%;34 项研究,3649 名参与者;中等 CoE)。需要二次干预:与 RIRS 相比,PCNL 可能减少需要二次干预(RR 0.31,95%CI 0.17-0.55;I = 61%;21 项研究,2005 名参与者;低 CoE)。
结论:尽管大多数研究存在缺陷,降低了我们对效应估计的确定性,使其主要为极低或低,但我们发现 PCNL 可能提高 SFRs 和减少需要二次干预,同时不影响主要并发症。与 RIRS 相比,输尿管狭窄率可能相似。我们预计本综述的结果将有助于就个人肾结石的治疗选择进行共同决策。
Cochrane Database Syst Rev. 2023-11-13
Cochrane Database Syst Rev. 2023-10-26
Cochrane Database Syst Rev. 2014-11-24
Cochrane Database Syst Rev. 2009-10-7
Cochrane Database Syst Rev. 2019-2-6